HARARE — The United States has launched lenacapavir (LEN) in Zimbabwe, a long‑acting injectable HIV prevention drug that will be administered twice yearly and is expected to support 271,000 people over the next three years while preventing more than 9,000 new infections, U.S. officials said at the national rollout.